Last reviewed · How we verify

Ad5FGF-4 — Competitive Intelligence Brief

Ad5FGF-4 (Ad5FGF-4) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy / Angiogenic agent. Area: Cardiovascular.

phase 3 Gene therapy / Angiogenic agent Fibroblast Growth Factor 4 (FGF-4) Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

Ad5FGF-4 (Ad5FGF-4) — Angionetics Inc.. Ad5FGF-4 is a gene therapy that delivers fibroblast growth factor 4 (FGF-4) via an adenovirus vector to promote angiogenesis and improve blood flow in ischemic tissues.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ad5FGF-4 TARGET Ad5FGF-4 Angionetics Inc. phase 3 Gene therapy / Angiogenic agent Fibroblast Growth Factor 4 (FGF-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy / Angiogenic agent class)

  1. Angionetics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ad5FGF-4 — Competitive Intelligence Brief. https://druglandscape.com/ci/ad5fgf-4. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: